Alnylam Pharmaceuticals (Germany) Today
| DUL Stock | EUR 135.65 0.30 0.22% |
Performance0 of 100
| Odds Of DistressLess than 22
|
Alnylam Pharmaceuticals is trading at 135.65 as of the 25th of April 2024. This is a -0.22 percent decrease since the beginning of the trading day. The stock's lowest day price was 135.65. Alnylam Pharmaceuticals has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Alnylam Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNYLAM PHARMACE operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 124.13 M outstanding shares. More on Alnylam Pharmaceuticals
Moving together with Alnylam Stock
| 0.74 | CSJA | CSL LTD SPONADR | PairCorr |
| 0.71 | CSJ | CSL Limited | PairCorr |
| 0.71 | VX1 | Vertex Pharmaceuticals | PairCorr |
| 0.78 | 1FW1 | WUXI BIOLOGICS UNSPADR2 | PairCorr |
Moving against Alnylam Stock
| 0.91 | NOVA | Novo Nordisk AS | PairCorr |
| 0.89 | MBG | Mercedes Benz Group Earnings Call This Week | PairCorr |
| 0.78 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.65 | C6T | China Construction Bank | PairCorr |
| 0.63 | ICK | Industrial and Commercial | PairCorr |
| 0.44 | BZG2 | PT Bank Central | PairCorr |
Alnylam Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alnylam Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alnylam Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Alnylam Pharmaceuticals (DUL) is traded on Frankfurt Exchange in Germany and employs 2,002 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 22.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alnylam Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Alnylam Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alnylam Pharmaceuticals classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 124.13 M outstanding shares.
Alnylam Pharmaceuticals has accumulated about 1.24 B in cash with (541.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.68.
Check Alnylam Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAlnylam Pharmaceuticals holds a total of 124.13 Million outstanding shares. The majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alnylam Ownership Details
Alnylam Stock Price Odds Analysis
In reference to a normal probability distribution, the odds of Alnylam Pharmaceuticals jumping above the current price in 90 days from now is about 80.5%. The Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Pharmaceuticals stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Alnylam Pharmaceuticals has a beta of -0.2397 suggesting as returns on the benchmark increase, returns on holding Alnylam Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Alnylam Pharmaceuticals is likely to outperform the market. Additionally, alnylam Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Alnylam Pharmaceuticals to move above the current price in 90 days from now is about 80.5 (This Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Stock to fall within a particular range of prices over 90 days) .
Alnylam Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Alnylam Pharmaceuticals market risk premium is the additional return an investor will receive from holding Alnylam Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Alnylam Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Alnylam Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Alnylam Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.47 | |||
| Standard Deviation | 2.3 | |||
| Variance | 5.28 | |||
| Risk Adjusted Performance | (0.08) |
Alnylam Stock Against Markets
Picking the right benchmark for Alnylam Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alnylam Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alnylam Pharmaceuticals is critical whether you are bullish or bearish towards Alnylam Pharmaceuticals at a given time. Please also check how Alnylam Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alnylam Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Alnylam Pharmaceuticals Corporate Management
Elected by the shareholders, the Alnylam Pharmaceuticals' board of directors comprises two types of representatives: Alnylam Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alnylam. The board's role is to monitor Alnylam Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alnylam Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alnylam Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Boyle | Chief Officer | Profile | |
| Kevin Fitzgerald | Head VP | Profile | |
| Michael BA | Ex Chairman | Profile | |
| Tolga MBA | Ex Officer | Profile | |
| Indrani JD | Chief VP | Profile | |
| Christine Lindenboom | Sr Communications | Profile | |
| MBA MBA | CEO Director | Profile |
How to buy Alnylam Stock?
Before investing in Alnylam Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alnylam Pharmaceuticals. To buy Alnylam Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alnylam Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Alnylam Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Alnylam Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Alnylam Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alnylam Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Already Invested in Alnylam Pharmaceuticals?
The danger of trading Alnylam Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alnylam Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alnylam Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alnylam Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |